Anyone have any idea why the Bioimplant division increased revenue by 30 percent this year but still had a 10 million loss, the same as last year? One off costs for purchase of Admedus Regen and redundancies?
It concerns me that all the cost savings according to the report seem to have been cutting R&D plus revenue increases for Infusions.
Ann: Annual Report to shareholders, page-40
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.41 |
Change
-0.500(5.05%) |
Mkt cap ! $202.9M | |||
| Open | High | Low | Value | Volume |
| $9.50 | $9.61 | $9.31 | $94.51K | 9.951K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 907 | $9.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.67 | 923 | 6 |
View Market Depth
| Last trade - 12.26pm 13/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |